Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey
No Thumbnail Available
Date
2019
Authors
Beksac, Meral
Seval, Guldane Cengiz
Paydas, Semra
Tuglular, Tulin Firatli
Arslan, Onder
Goker, Hakan
Kaynar, Leylagul
Altuntas, Fevzi
Atalay, Figen
Teke, Havva Uskudar
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
Keywords
elotuzumab, immunomodulatory drugs, Multiple myeloma